Shanghai Pharmaceuticals Holding Co., Ltd

12:30 PM - 12:45 PM (EDT), Monday, June 5, 2023 ・ Session Room 104B
• 2nd-largest and vertically-integrated pharma company in China ~ $35B revenue in 2022 across multiple therapeutic areas; Global Fortune 500; Global Forbes 2000
• Broadest network & access to top-tier clinical trial sites (i.e., teaching hospitals) to support clinical development (50+ pipeline assets across therapeutic areas and modalities)
• Largest Specialty Pharmaceutical Distribution throughout China, strengthened through acquisition of Cardinal Health China – responsible for 80% of first prescriptions of new specialty drugs in China
• Most expansive access to hospitals and pharmacists throughout China
• High-quality and large scle GMP manufacturing (50+ facilities with continuing expansion) covering various modalities including antibodies, ADCs, vaccines, oncolytic virus, peptides, AAV gene delivery system and other complex biologics
• Rare Disease leadership in China through SPH Rare – 21 marketed products, 16 new drugs in pipeline, 34 orphan drug categories
601607.SH, 2607.HK
Shanghai Stock Exchange; Hong Kong Exchanges and Clearing Limited
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Company HQ Country:
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Of the many products in development by SPH (2nd largest Chinese pharmaceutical company), this presentation will introduce SPH3127 as a novel treatment for hypertension
Development Phase of Primary Product:
NDA Preparation/In Review
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Placeholder Photo
Shanghai Pharma Biotherapeutics USA Inc